[HTML][HTML] Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular …

P Indu, MR Rameshkumar, N Arunagirinathan… - Journal of Infection and …, 2020 - Elsevier
Background Outbreak of COVID-19 has been recognized as a global health concern since it
causes high rates of morbidity and mortality. No specific antiviral drugs are available for the …

Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-O-ribose methyltransferase

RJ Khan, RK Jha, GM Amera, M Jain… - Journal of …, 2021 - Taylor & Francis
The recent pandemic associated with SARS-CoV-2, a virus of the Coronaviridae family, has
resulted in an unprecedented number of infected people. The highly contagious nature of …

Impact of remdesivir incorporation along the primer strand on SARS-CoV-2 RNA-Dependent RNA polymerase

S Naseem-Khan, MB Berger, EM Leddin… - Journal of chemical …, 2022 - ACS Publications
Remdesivir was the first antiviral drug that received emergency use authorization from the
United States Food and Drug Administration and is now formally approved to treat COVID …

Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target

Y Gao, L Yan, Y Huang, F Liu, Y Zhao, L Cao, T Wang… - BioRxiv, 2020 - biorxiv.org
Abstract A novel coronavirus (2019-nCoV) outbreak has caused a global pandemic resulting
in tens of thousands of infections and thousands of deaths worldwide. The RNA-dependent …

Theoretical insights into the effect of halogenated substituent on the electronic structure and spectroscopic properties of the favipiravir tautomeric forms and its …

LC Assis, AA de Castro, JPA de Jesus, EFF da Cunha… - Rsc Advances, 2021 - pubs.rsc.org
In this study, we systematically investigated the electronic structure, spectroscopic (nuclear
magnetic resonance, infrared, Raman, electron ionization mass spectrometry, UV-Vis …

[PDF][PDF] Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?

RN Dallocchio, A Dessì, A De Vito… - European Review for …, 2021 - researchgate.net
OBJECTIVE: Since no effective therapy exists, we aimed to test existing HIV antivirals for
combination treatment of Coronavirus disease 19 (COVID-19). MATERIALS AND …

[HTML][HTML] Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses

J Li, Y Wang, K Solanki, R Atre, M Lavrijsen, Q Pan… - Antiviral Research, 2023 - Elsevier
Nirmatrelvir is the main component of Paxlovid, an oral antiviral drug approved for the
treatment of COVID-19 caused by SARS-COV-2 infection. Nirmatrelvir targets the main …

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

P Li, Y Wang, M Lavrijsen, MM Lamers, AC de Vries… - Cell research, 2022 - nature.com
Dear Editor, Since the first outbreak in late 2019, the RNA genome of SARS-CoV-2 has
been undergoing constant evolution. This is largely attributed to the viral polymerase that is …

Remdesivir strongly binds to both RNA-dependent RNA polymerase and main protease of SARS-CoV-2: Evidence from molecular simulations

HL Nguyen, NQ Thai, DT Truong… - The Journal of Physical …, 2020 - ACS Publications
The outbreak of a new coronavirus SARS-CoV-2 (severe acute respiratory syndrome–
coronavirus 2) has caused a global COVID-19 (coronavirus disease 2019) pandemic …

Molecular dynamics simulations reveal the interaction fingerprint of remdesivir triphosphate pivotal in allosteric regulation of SARS-CoV-2 RdRp

M Srivastava, L Mittal, A Kumari… - Frontiers in molecular …, 2021 - frontiersin.org
The COVID-19 pandemic has now strengthened its hold on human health and coronavirus'
lethal existence does not seem to be going away soon. In this regard, the optimization of …